Local Institution

Prague 180 85

0 studies enrolling now · 52 studies all time

What they study most

Acute Coronary Syndrome, Acute Coronary Syndromes, Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Arthritis, Psoriatic, Atrial Fibrillation, Atrial Flutter, Bipolar Disorder, Breast Cancer, Cancer, Cancer, Hepatocellular, Chronic Hepatitis B, Chronic Kidney Failure

Studies at this site

• A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer — Completed
• Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib — Completed
• A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania — Completed
• A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer — Completed
• Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) — Completed
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma — Completed
• Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis — Completed
• Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate — Completed
• Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy — Completed
• Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis — Stopped early
• Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure — Completed
• Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone — Completed
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin — Completed
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma — Completed
• Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes — Completed
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab — Completed
• Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir — Completed
• PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma — Completed
• Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• A Phase III Study of Apixaban in Patients With Atrial Fibrillation — Completed
• An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer — Withdrawn before enrolling
• Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant — Completed
• A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia — Completed
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker — Completed
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML — Completed
• Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) — Completed
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes — Completed
• Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes — Completed
• Phase III Acute Coronary Syndrome — Stopped early
• Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
• PoC in Rheumatoid Arthritis With Methotrexate — Completed
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed
• Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis — Completed
• Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma — Completed
• Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML — Completed
• Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• Study of Aripiprazole in Patients With Bipolar I Disorder — Completed
• Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer — Completed
• Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C — Withdrawn before enrolling
• Remission and Joint Damage Progression in Early Rheumatoid Arthritis — Completed
• Dose Ranging Study With LT, Monotherapy, PPAR — Completed